Campylobacter pylori--therapy review.

Area of Science:

• Microbiology
• Infectious Diseases
• Gastroenterology

Background:

• Campylobacter pylori (C. pylori) exhibits in vitro antibiotic sensitivity, but in vivo efficacy is limited.
• Current treatment regimens often lead to high recurrence rates for C. pylori infections.
• Sustained C. pylori negativity one month post-therapy indicates successful eradication.

Purpose of the Study:

• To evaluate the efficacy of different treatment strategies for Campylobacter pylori eradication.
• To identify effective monotherapy, dual therapy, and triple therapy regimens.
• To assess the long-term eradication rates of C. pylori infections.

Main Methods:

• In vivo assessment of various treatment regimens including monotherapy, dual therapy, and triple therapy.
• Evaluation of C. pylori eradication rates at one month and twelve months post-treatment.
• Comparison of treatment outcomes for different combinations of antibiotics and bismuth salts.

Main Results:

• Bismuth salt monotherapy eradicated C. pylori in approximately 19% of cases.
• Dual therapy with bismuth and ampicillin or tinidazole achieved eradication rates of 32% and 78%, respectively.
• Preliminary triple therapy regimens (bismuth, amoxicillin, metronidazole or bismuth, tetracycline, metronidazole) demonstrated over 90% eradication success.

Conclusions:

• Monotherapy and dual therapy regimens show limited efficacy in eradicating C. pylori.
• Triple therapy regimens involving bismuth, amoxicillin/metronidazole or tetracycline/metronidazole are highly effective for C. pylori eradication.
• Long-term eradication is achievable with effective treatment strategies, significantly reducing recurrence rates.